John Ford

John Ford is an accomplished executive and entrepreneur in the biopharmaceutical industry with extensive experience in drug development and leadership roles. Currently serving as Executive Chairman of ARMGO Pharma, Inc., Chairman of Complement Therapeutics, and CEO of Enterprise Therapeutics, Ford has a track record of overseeing innovative therapies targeting cardiac, musculoskeletal, and neurological disorders, as well as complement-related diseases. Previously, Ford co-founded and led several companies including Ario Pharma and Xention Discovery, and held key operational roles at Metrion Biosciences and Dezima Pharma, which was acquired by Amgen. Ford holds a BSc (1st Class) and a PhD in Biochemistry & Pharmacology from the University of Leeds.